Company intelligence / Profile preview

MindMed

New York City, New York, United Statesmindmed.co ↗

Ownership: Public · MNMD
Development stage: Phase 2

Overview

MindMed is advancing a pipeline of novel product candidates targeting brain health disorders. Its lead program, MM120 ODT (lysergide D-tartrate), is in Phase 3 trials for generalized anxiety disorder and preparing for Phase 3 in major depressive disorder. Early clinical data show statistically significant improvements in GAD scores. Another candidate, MM402 ((R)-(-)-MDMA), is in Phase 1 trials for autism spectrum disorder.

Therapeutic areas: Psychiatry
Modalities: Small moleculePsychedelic compoundPsychoplastogen
Industry: Biotech

Drug pipeline

2 assets

lysergic acid diethylamide D-tartrate

1 more asset in the full pipeline.

Request access →

Partnerships

None publicly disclosed with major pharma as of June 2025.

Financials

Market cap: $1.6B
Total revenue: $0
Enterprise value: $479.3M

Beyond the preview

Go deeper on MindMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MindMed.

Explore the full profile